Judith M. Müller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Judith M. Müller has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Roland Schüle
Uniklinikum Freiburg
5 shared publications - Eric Metzger
Uniklinikum Freiburg
2 shared publications Adrien Eberlin
Urologische Klinik und Zentrale Klinische Forschung, Klinikum der Universität Freiburg 1 , Breisacherstrasse 66, 79106 Freiburg , Germany
1 shared publication- Anja Müller
Division of Molecular Hematology, Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
1 shared publication - Anne Marie Staehle
Department of Hematology/Oncology, Medical Center - University of Freiburg, Freiburg, Germany
1 shared publication August Sigle
Klinik für Urologie und Zentrale Klinische Forschung, Klinikum der Universität Freiburg, Freiburg, Germany
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 619
Lysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation
The lysine-specific demethylase 1 (LSD1) regulates hematopoietic stem cell differentiation and has been identified as a therapeutic target in hematological disorders. LSD1 demethylates mono and dimethylated histones 3 at lysine 4 and 9. In addition, it acts as a scaffold for the formation of chromatin-modifying complexes that regulates the transcription of myeloid-lineage-specific genes in complex with GFI1, a transcriptional repressor. While both enzymatic and non-enzymatic functions of LSD1 have been well defined, the relative importance of these two functions in hematopoiesis remains incompletely understood. Here, we investigated the contribution of enzymatic and non-enzymatic functions of LSD1 to myelopoiesis. We show that myeloid differentiation is independent of the enzymatic functions of LSD1 but requires the non-enzymatic, scaffolding function, which directs GFI1 binding to target sequences. In the absence of the LSD1 protein, GFI1 DNA binding is diminished, and myeloid cell differentiation arrests at an immature, myelomonocytic-like cell stage, which overexpresses Prtn3. We provide functional data implicating Prtn3 as an effector of the stem cell expansion and myeloid maturation block caused by the loss of LSD1.
- 15 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 619
Open AccessLysine-specific demethylase 1 regulates hematopoietic stem cell expansion and myeloid cell differentiation
The lysine-specific demethylase 1 (LSD1) regulates hematopoietic stem cell differentiation and has been identified as a therapeutic target in hematological disorders. LSD1 demethylates mono and dimethylated histones 3 at lysine 4 and 9. In addition, it acts as a scaffold for the formation of chromatin-modifying complexes that regulates the transcription of myeloid-lineage-specific genes in complex with GFI1, a transcriptional repressor. While both enzymatic and non-enzymatic functions of LSD1 have been well defined, the relative importance of these two functions in hematopoiesis remains incompletely understood. Here, we investigated the contribution of enzymatic and non-enzymatic functions of LSD1 to myelopoiesis. We show that myeloid differentiation is independent of the enzymatic functions of LSD1 but requires the non-enzymatic, scaffolding function, which directs GFI1 binding to target sequences. In the absence of the LSD1 protein, GFI1 DNA binding is diminished, and myeloid cell differentiation arrests at an immature, myelomonocytic-like cell stage, which overexpresses Prtn3. We provide functional data implicating Prtn3 as an effector of the stem cell expansion and myeloid maturation block caused by the loss of LSD1.
- Open Access
- 30 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Mitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity and prostate cancer growth
Prostate cancer (PCa) growth depends on de novo lipogenesis controlled by the mitochondrial pyruvate dehydrogenase complex (PDC). In this study, we identify lysine methyltransferase (KMT)9 as a regulator of PDC activity. KMT9 is localized in mitochondria of PCa cells, but not in mitochondria of other tumor cell types. Mitochondrial KMT9 regulates PDC activity by monomethylation of its subunit dihydrolipoamide transacetylase (DLAT) at lysine 596. Depletion of KMT9 compromises PDC activity, de novo lipogenesis, and PCa cell proliferation, both in vitro and in a PCa mouse model. Finally, in human patients, levels of mitochondrial KMT9 and DLAT K596me1 correlate with Gleason grade. Together, we present a mechanism of PDC regulation and an example of a histone methyltransferase with nuclear and mitochondrial functions. The dependency of PCa cells on mitochondrial KMT9 allows to develop therapeutic strategies to selectively fight PCa.
- 30 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessMitochondrial KMT9 methylates DLAT to control pyruvate dehydrogenase activity and prostate cancer growth
Prostate cancer (PCa) growth depends on de novo lipogenesis controlled by the mitochondrial pyruvate dehydrogenase complex (PDC). In this study, we identify lysine methyltransferase (KMT)9 as a regulator of PDC activity. KMT9 is localized in mitochondria of PCa cells, but not in mitochondria of other tumor cell types. Mitochondrial KMT9 regulates PDC activity by monomethylation of its subunit dihydrolipoamide transacetylase (DLAT) at lysine 596. Depletion of KMT9 compromises PDC activity, de novo lipogenesis, and PCa cell proliferation, both in vitro and in a PCa mouse model. Finally, in human patients, levels of mitochondrial KMT9 and DLAT K596me1 correlate with Gleason grade. Together, we present a mechanism of PDC regulation and an example of a histone methyltransferase with nuclear and mitochondrial functions. The dependency of PCa cells on mitochondrial KMT9 allows to develop therapeutic strategies to selectively fight PCa.
- 3 June 2021
- Published by Springer Nature
- p. 1-7
Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor
- 3 June 2021
- Published by Springer Nature
- p. 1-7
Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor
- 1 January 2021
- Published by Springer Nature
- p. 1415-1421
Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor
- 1 January 2021
- Published by Springer Nature
- p. 1415-1421
Sex Steroid Receptors: Androgen Receptor, Estrogen Receptors, Progesterone Receptor
- Open Access
- 15 March 2018
- Published by The Company of Biologists in Development
- Vol. 145 (6) , dev.158543
The histone acetyltransferase inhibitor Nir regulates epidermis development
Nir/ Noc2l is an inhibitor of histone acetyl-transferases (INHAT). In addition to its function on histone acetylation, Nir binds to p53 and TAp63 to regulate their activity. Here, we show that epidermis-specific ablation of Nir impairs epidermal stratification and barrier function, thereby causing perinatal lethality. Nir-deficient epidermis lacks appendages and remains single layered during embryogenesis. Cell proliferation is inhibited, whereas apoptosis and p53 acetylation is increased, indicating that Nir is controlling cell proliferation by limiting p53 acetylation. Transcriptome analysis revealed that Nir regulates expression of essential factors of epidermal development, such as keratins, integrins, and laminins. Furthermore, Nir binds to and controls expression of p63 and limits H3K18ac at the p63 promoter. Corroborating stratification defects, asymmetric cell divisions were virtually absent in Nir-deficient mice, suggesting that Nir is required for correct mitotic spindle orientation. In summary, our data define Nir as a key regulator of skin development.
- 15 March 2018
- Published by The Company of Biologists in Development
- Vol. 145 (6) , dev.158543
Open AccessThe histone acetyltransferase inhibitor Nir regulates epidermis development
Nir/ Noc2l is an inhibitor of histone acetyl-transferases (INHAT). In addition to its function on histone acetylation, Nir binds to p53 and TAp63 to regulate their activity. Here, we show that epidermis-specific ablation of Nir impairs epidermal stratification and barrier function, thereby causing perinatal lethality. Nir-deficient epidermis lacks appendages and remains single layered during embryogenesis. Cell proliferation is inhibited, whereas apoptosis and p53 acetylation is increased, indicating that Nir is controlling cell proliferation by limiting p53 acetylation. Transcriptome analysis revealed that Nir regulates expression of essential factors of epidermal development, such as keratins, integrins, and laminins. Furthermore, Nir binds to and controls expression of p63 and limits H3K18ac at the p63 promoter. Corroborating stratification defects, asymmetric cell divisions were virtually absent in Nir-deficient mice, suggesting that Nir is required for correct mitotic spindle orientation. In summary, our data define Nir as a key regulator of skin development.
- 27 May 2004
- Vol. 24, 921-7
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Abnormal signal transduction arising from integrins and protein tyrosine kinases has been implicated in the initiation and progression of a variety of human cancers. Integrin-mediated signal transduction pathways require regulated cytoplasmic protein-protein interactions. However, little is known about integrin-associated proteins and ovarian cancer. In our study we investigated the association of pp125FAK, a cytoplasmic tyrosine kinase, involved in anchorage-independent growth of tumor cells, and the Four and a Half LIM domain (FHL) protein FHL2, which was recently shown to interact with integrins. Our data demonstrated that pp125FAK and FHL2 form a protein complex in human ovarian carcinoma. Furthermore, we showed that pp125FAK is overexpressed in epithelial ovarian cancer, but virtually absent in normal ovary. Our immunohistochemistry data showed that FHL2 protein expression is also augmented in epithelial ovarian cancer. Taken together, our results demonstrated for the first time FHL2 expression in human ovarian cancer cells, suggesting an important functional role of pp125FAK and FHL2 complex in gynecologic malignancies.
- 27 May 2004
- Vol. 24, 921-7
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Abnormal signal transduction arising from integrins and protein tyrosine kinases has been implicated in the initiation and progression of a variety of human cancers. Integrin-mediated signal transduction pathways require regulated cytoplasmic protein-protein interactions. However, little is known about integrin-associated proteins and ovarian cancer. In our study we investigated the association of pp125FAK, a cytoplasmic tyrosine kinase, involved in anchorage-independent growth of tumor cells, and the Four and a Half LIM domain (FHL) protein FHL2, which was recently shown to interact with integrins. Our data demonstrated that pp125FAK and FHL2 form a protein complex in human ovarian carcinoma. Furthermore, we showed that pp125FAK is overexpressed in epithelial ovarian cancer, but virtually absent in normal ovary. Our immunohistochemistry data showed that FHL2 protein expression is also augmented in epithelial ovarian cancer. Taken together, our results demonstrated for the first time FHL2 expression in human ovarian cancer cells, suggesting an important functional role of pp125FAK and FHL2 complex in gynecologic malignancies.